Modular Medical (MODD) announced the start of production of validation lots for its Pivot tubeless patch pump’s disposable cartridge and infusion set. Achievement of this manufacturing milestone keeps the Company on schedule for commercial launch in Q1 2026, subject to receipt of FDA 510(k) clearance. “We are excited to hit this pivotal manufacturing validation on schedule, bringing us closer to delivering our Pivot pump’s game-changing simplicity to patients underserved by current options,” said Jeb Besser, CEO. “This further derisks our expected path to Q1 2026 commercialization, which is subject to FDA response to our current 510(k) application, and would put us in position to drive market disruption.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MODD:
- Modular Medical Shareholders Approve Reverse Split and Expansion
- Modular Medical Granted Nasdaq Extension to Regain Compliance
- Modular Medical receives 180-day extension to regain Nasdaq compliance
- Modular Medical Completes Public Offering for $4.68 Million
- Modular Medical announces common stock and warrant offering, no amount given
